109
Participants
Start Date
August 17, 2020
Primary Completion Date
October 29, 2024
Study Completion Date
October 29, 2024
TAK-981
TAK-981 IV infusion.
Pembrolizumab
Pembrolizumab IV infusion.
Universitaetsspital Bern - Inselspital, Bern
Kantonsspital Winterthur, Winterthur
Kantonsspital Muensterlingen, Münsterlingen
Klinicki bolnicki centar Zagreb, Zagreb
Montefiore Einstein Cancer Center - BRANY - PPDS, The Bronx
UPMC Hillman Cancer Center, Pittsburgh
Fox Chase Cancer Center, Philadelphia
The Center for Cancer and Blood Disorders - PPDS, Bethesda
University Hospital Centre Split, Split
Virginia Cancer Specialists (Fairfax) - USOR, Fairfax
University of Virginia Health System, Charlottesville
University of North Carolina at Chapel Hill, Chapel Hill
Georgia Cancer Center at Augusta University, Augusta
Clinical Hospital Centre Osijek, Osijek
General Hospital Pula, Pula
University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City
University of Texas Southwestern Medical Center, Dallas
START South Texas Accelerated Research Therapeutics, San Antonio
HonorHealth, Scottsdale
University of California Irvine Medical Center, Orange
Stanford Cancer Institute (SCI), Stanford
Providence Cancer Institute, Franz Clinic, Portland
The First Affiliated Hospital, Zhejiang University School of Medicine - PPDS, Hangzhou
Sun Yat-Sen University Cancer Center, Guangzhou
Yale Cancer Center, New Haven
Morristown Medical Center, Morristown
Cancer Institute of New Jersey, New Brunswick
Instituto de Oncologia Do Parana, Curitiba
ONCOSITE Centro de Pesquisa Clinica Em Oncologia, Ijuí
Hospital de Clinicas de Porto Alegre (HCPA) - PPDS, Porto Alegre
Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS), Porto Alegre
Fundacao Pio XII Hospital de Cancer de Barretos, Barretos
Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto
Cetus Hospital Dia Oncologia, Belo Horizonte
INCA Instituto Nacional de Cancer, Rio de Janeiro
Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, Rio de Janeiro
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
National Cancer Center East, Kashiwa-Shi
National Cancer Center Hospital, Chuo-Ku
The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Chuo-Ku
Pauls Stradins Clinical University Hospital, Riga
Riga East Clinical University Hospital Latvian Oncology Center, Riga
Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas
Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas
National Cancer Institute, Vilnius
Uniwersyteckie Centrum Kliniczne-Ul. Smoluchowskiego 17, Gdansk
Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz
Instytut Medyczny Santa Familia Sp. z o. o., Lodz
Specjalistyczna Praktyka Lekarska Slawomir Mandziuk, Lublin
Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie, Olsztyn
Med-Polonia Sp. z o.o., Poznan
Centrum Terapii Wspolczesnej, Lodz
Lead Sponsor
Takeda Development Center Americas, Inc.
INDUSTRY
Takeda
INDUSTRY